Haemophilus ducreyi 35000HP contains a homologue of the luxS gene, which encodes an enzyme that synthesizes autoinducer 2 (AI-2) in other gram-negative bacteria. H. ducreyi 35000HP produced AI-2 that functioned in a Vibrio harveyi-based reporter system. A H. ducreyi luxS mutant was constructed by insertional inactivation of the luxS gene and lost the ability to produce AI-2. Provision of the H. ducreyi luxS gene in trans partially restored AI-2 production by the mutant. The luxS mutant was compared with its parent for virulence in the human challenge model of experimental chancroid. The pustule-formation rate in 5 volunteers was 93.3% (95% confidenc interval, 81.7%-99.9%) at 15 parent sites and 60.0% (95% confid nce interval, 48.3%-71.7%) at 15 mutant sites (1-tailed ). Thus, the luxS mutant was partially attenuated for P ! .001 virulence. This is the firs report of AI-2 production contributing to the pathogenesis of a genital ulcer disease.
in its genome (GenBank accession no. NC002940) a homologue that is 72% identical to the V. harveyi luxS gene. Although production of AI-2 by H. ducreyi has not been demonstrated, the presence of luxS and the fact that H. ducreyi forms microcolonies [11] (a key feature of biofil formation [12] in vitro) and aggregates during human infection [13] suggests the possible existence of a quorum-sensing mechanism for gene regulation in H. ducreyi. To study the pathogenesis of H. ducreyi infection, we developed an experimental model of infection in human volunteers [14, 15] . The model involves the injection of the human-passaged H. ducreyi strain 35000HP and its derivatives into the skin of the upper arm [16, 17] . There are sex and host effects on outcome in the model [18] . In mutant-parent comparison trials, volunteers are inoculated with multiple doses of 35000HP and of mutants made in the 35000HP background on opposite arms and serve as their own controls for sex and host effects [17] . Of the 20 mutants tested to date, 11 are virulent (ie, form pustules at doses similar to the parent) [17, 19, 20] , 3 are partially attenuated (ie, form pustules at doses 2-3-fold that of the parent or at lower rates at doses equivalent to the parent) [21] [22] [23] , and 6 are attenuated (ie, unable to form pustules even at doses 10-fold that of the parent) [24] [25] [26] [27] [28] [29] . Thus, the model discriminates among H. ducreyi gene products for their ability to contribute to the development of pustules.
In the present study, we report that H. ducreyi synthesizes an AI-2-like molecule. We show that inactivation of the H. ducreyi luxS gene decreased the virulence of this pathogen in human volunteers.
METHODS
Bacterial strains, plasmids, and culture conditions. H. ducreyi strains (table 1) were routinely cultured on chocolate agar plates and incubated at 33ЊC in a humidifie atmosphere containing 95% air and 5% CO 2 . For in vitro experiments, strains were grown at 33ЊC in a gyratory water bath at 100 rpm in a Columbia broth-based (CB) medium, as described elsewhere [33] . H. ducreyi cells used as inocula in the human challenge model were grown as described elsewhere [15] . Plasmids used in this study are listed in table 1. When appropriate, medium was supplemented with chloramphenicol or kanamycin at fi al concentrations of 1 and 30 mg/mL, respectively. V. harveyi strains were grown in AB medium [30] . E. coli DH5a and TOP10 strains were used for general cloning manipulations and were grown in Luria-Bertani medium supplemented with kanamycin (50 mg/mL) or chloramphenicol (30 mg/mL) when appropriate for maintenance of plasmids. Plasmid constructs were transformed into and isolated from E. coli HB101 before they were electroporated into H. ducreyi.
Construction of a H. ducreyi luxS mutant. The luxS gene was amplifie by polymerase chain reaction (PCR) from H. ducreyi 35000HP chromosomal DNA using oligonucleotide primers luxS-7 (5 -ATGCGGAGCAGTTGACTAAC-3 ) and luxS-8 (5 -ATTCTGCACTACGAATACCC-3 ). The resulting 3.6-kb amplicon was ligated into the pCRII Blunt TOPO vector to obtain pRB302. The DEcat cartridge [32] was ligated into a unique SwaI site in luxS in pRB302 to obtain pRB303. E. coli HB101 was transformed with pRB303; the plasmid was purif ed and linearized with SmaI. The linearized construct was gelpurifie and electroporated into 35000HP. Transformants were allowed to recover in CB medium for 5 h, after which they were transferred to chocolate agar plates containing chloramphenicol (1 mg/mL). Following an incubation period of 72-144 h, colonies were screened for the presence of a mutated luxS gene by direct single-colony PCR amplificatio using oligonucleotide primers luxS-13 (5 -CTTTTCTCTGGTGAGATCA-TTACAG-3 ) and luxS-14 (5 -TTTAACGCCATCGACTAGA-GTC-3 ). The luxS mutant was designated 35000HP.303.
Complementation of 35000HP.303. To complement 35000 HP.303, a fragment that included the luxS gene together with 657-nt upstream and 164-nt downstream DNA was used. Because luxS appears to be in an operon with at least 2 other genes, to ensure transcription the promoter region (Ϫ1 to Ϫ150 nt) of the p-ACYC184 cat gene [34] was inserted in front of the luxS gene (at Ϫ1 nt) by means of overlapping extension PCR [35] . Three amplicons were used in this procedure. Fragment 1 was obtained by amplificatio of the luxS upstream region using primers luxSBamHI-F (5 -ACGCGGATCCATGCTAAAAAACAGATAAAAT-CAGATAAAA-3 ) and luxS-2 (5 -GTTGCCCCAGGGCTTCC-CGGTATCAACATTTTACTCCAAATTATAT-3 ). Fragment 2 involved amplificatio of the cat promoter region using primers catP-3 (5 -GTTGATACCGGGAAGCCCTGGGCCAAC-3 ) and catP-4 (5 -TTTAGCTTCCTTAGCTCCTGAAAA-3 ). Fragment 3 required amplificatio of luxS and its downstream region using primers luxS-5 (5 -TTTTCAGGAGCTAAGGAAGCTAAAATGC-CTTTATTAGATAGTTTT-3 ) and luxS-BamHI-R (5 -ACGC-GGATCCCTTTTCTCTGGTGAGATCATTACAG-3 ). Underlined sequences indicate BamHI sites, and sequences in boldface type indicate regions complementary to fragment 2. All 3 fragments were gel-purified and equivalent amounts were used together as templates in the fina overlapping extension PCR with primers luxS-BamHI-F and luxS-BamHI-R. The resulting amplicon was ligated as a BamHI fragment into plasmid p-ACYC177 [34] , and the resultant construct, designated pML132, was transformed into 35000HP.303 as described above. Nucleotide sequence analysis verifie the absence of PCR-induced mutations in the fina cloned amplicon. The complemented mutant was designated 35000HP.303(pML132).
Southern blot analysis. Chromosomal DNA from 35000HP and 35000HP.303 was digested with EcoRV and used in Southern blot analysis. The probe for the luxS gene was obtained by PCR, using the primers luxS-9 (5 -TCGATTTAA-CCATTCTTCATC-3 ) and luxS-10 (5 -TATTGATATTTCAC-CGATGG-3 ) to amplify a 283-bp fragment from 35000HP chromosomal DNA. The probe for the cat cartridge was obtained by using the primers DeltaEcat(F) (5 -CCGTTTTTA-TCAGGCTCTGG-3 ) and DeltaEcat(R) (5 -TTTTGCCGT-TACGCACCAC-3 ) to amplify an ∼1.3-kb fragment from pACYC184DEcat containing the cat cartridge. Both probes were labeled by using the PCR DIG labeling mix (Roche Applied Sciences).
Reverse-transcription PCR and real-time reverse-transcription PCR. A 500-mL volume of stop buffer (200 mmol/L TrisCl [pH 8], 20 mmol/L ethylenediaminetetraacetic acid, and 20 mmol/L sodium azide) was added to 10 mL of midlogarithmicphase bacterial culture immediately before collection by centrifugation. Total RNA was isolated from 35000HP immediately on harvest by means of an RiboPure-Bacteria kit (Ambion). After isolation, RNA was treated with DNaseI (Ambion) for 1 h at 37ЊC and purif ed using the RNeasy system (Qiagen). Primers used for reverse-transcription PCR (RT-PCR) (f gure 1A) were designed using the 35000HP genome sequence and had the following sequences: HD0369-HD0370 (5 -GTTATACGATGGAT-ATTTCT-3 , forward), HD0369-HD0370 (5 -CTCCATATTAG-GGCGACAAA-3 , reverse), HD0370-HD0371 (5 -ACACAAATT-CCTGAGCTGAA-3 , forward), and HD0370-HD0371 (5 -ATAT-AAAAGGATAAATACGC-3 , reverse). Brief y, 2 mg of RNA was reverse-transcribed using TaqMan RT reagents (Applied Biosystems), in accordance with the manufacturer's instructions. The resultant cDNA was used as PCR template with the primer sets indicated above. A reaction lacking reverse transcriptase was used as a PCR template to control for contaminating DNA. Real-time RT-PCR [36] was used to measure relative expression levels of HD0371 in 35000HP and 35000HP.303, using oligonucleotide primers 5 -ATCGAGATTGGACGTTGGTA-3 and 5 -CTCGTC-TAGCGCTTTCACC-3 .
Autoinducer bioassay. Cell-free culture supernatants were prepared as described elsewhere [30] . Briefl , H. ducreyi strains were grown in CB medium overnight and used to inoculate CB medium to an initial optical density at 600 nm of 0.05. Portions (500 mL) of the culture were harvested every hour for 16 h. Supernatants were prepared by centrifugation at 2500 g for 5 min. These fluid were then sterilized with a 0.2-mm-pore filte and stored at Ϫ20ЊC until used. As a positive control, cell-free culture supernatant was also prepared from V. harveyi strain BB120, as described elsewhere [30] . The autoinducer bioassay was performed as follows: 10-mL portions of cell-free culture supernatants were added to a sterile, black, clear-bottomed 96-well microtiter plate. The V. harveyi reporter strain BB170 was grown for 14-16 h in AB medium to a density of colony-forming units (CFUs)/mL and diluted 1:5000 9 2.4 ϫ 10 in fresh AB medium. A 90-mL portion of this cell suspension was added to each of the wells containing the supernatants. Negative control wells contained 90 mL of cells and 10 mL of either CB or AB medium. The microtiter plate was shaken at 175 rpm at 30ЊC, and light production was measured after 5 h in a SpectraFluor Plus fluo ometer (Tecan) set to luminescence mode with a 200-ms integration time and a gain setting of 100. Human inoculation experiments. Healthy volunteers 121 years of age were recruited for the study. Subjects gave informed consent for participation and for human immunodef ciency virus serology, in accordance with the human experimentation guidelines of the US Department of Health and Human Services and the Institutional Review Board of Indiana University-Purdue University of Indianapolis. The experimental protocol, preparation and inoculation of the bacteria, calculation of the estimated delivered dose (EDD), and clinical observations were done exactly as described elsewhere [14, 15] . Stocks of 35000HP and 35000HP.303 used for the human inoculation experiments were prepared according to US Food and Drug Administration guidelines (BB-IND 13064). Subjects were observed until they reached clinical end point, which was define as resolution of all sites, development of a pustule that was either painful or 14 mm in diameter, or 14 days after inoculation. At end point, subjects were treated with 1 dose of oral ciprofl xacin.
The trial was designed to test whether the luxS mutant was impaired in its ability to cause pustules relative to the parent in a multistage dose-ranging study with a minimum of 2 stages [17] . An EDD of 90 CFUs of 35000HP causes a papule-formation rate of 95% and a pustule-formation rate of 50% in naive subjects. We attempted to inoculate each subject in the firs group with 90 CFUs of 35000HP at 3 sites on one arm and with 45, 90, and 180 CFUs of 35000HP.303 on the other arm, so that the dose of the mutant was in a range that causes pustules if the mutant was virulent. If inoculation of the mutant and parent caused pustules in the firs group of subjects, the second group was inoculated with similar doses. Comparison of papule-and pustule-formation rates for the 2 strains was performed using a logistic regression model with generalized estimating equations (GEEs) to account for the correlation among sites within the same individual, as described elsewhere [27] . The GEE sandwich estimate for the standard errors was used to calculate 95% confidenc intervals (CIs) for these rates.
To confi m that the inocula contained or lacked the cat cartridge and that the cat cartridge was not lost by the mutant during the course of infection, individual colonies from the inocula, surface cultures, and biopsy specimens were scored for susceptibility to chloramphenicol on chloramphenicol-containing chocolate agar plates, as described elsewhere [16] . Construction and characterization of a H. ducreyi 35000HP luxS mutant. To determine whether the H. ducreyi luxS homologue might be involved in virulence expression, we constructed a luxS mutant by inserting a cat cartridge into the luxS ORF, as described in Methods. PCR analysis of the luxS gene in this mutant indicated that it was ∼1.3 kb larger than the .303 had similar outer membrane protein and lipooligosaccharide expression patterns, as analyzed by SDS-PAGE, and had similar growth rates in the broth used to prepare inocula for human challenge experiments (data not shown). AI-2 production by H. ducreyi 35000HP. To investigate whether H. ducreyi-conditioned medium had AI-2 activity, a bioluminescence assay was performed using the V. harveyi reporter strain BB170. V. harveyi BB170 cannot synthesize its own AI-2; only AI-2 present in the conditioned medium should induce luminescence [37] . Cell-free culture supernatants collected during the growth of 35000HP and 35000HP.303 were incubated with BB170. V. harveyi BB120-conditioned medium was used as a positive control. Strain 35000HP produced signif cant amounts of AI-2 activity, compared with 35000HP.303 (f gure 2). Peak activity was observed at midexponential phase and then decreased during stationary phase, which correlates well with results obtained with other bacteria that produce AI-2 [30] . Expression of luxS in trans partially restored the ability of 35000HP.303 to induce luminescence in this assay (f gure 2).
RESULTS

Identificatio of the
Human challenge trial. Eight healthy adults (4 males and 4 females; 6 white and 2 black; age range, 25-45 years; mean age ‫ע‬ standard deviation [SD], years) volunteered for 38 ‫ע‬ 9 the study. Two subjects were excluded because they did not meet inclusion criteria. One subject withdrew on the day of inoculation. Three subjects (volunteers 318, 319, and 322) were inoculated in the firs iteration and two subjects (volunteers 323 and 328) were inoculated in the second iteration. In the firs iteration, each subject was infected with 143 CFUs of 35000HP at 3 sites on one arm and with 59, 118, and 235 CFUs of 35000HP.303 on the other arm (table 2) . Pustules formed at 8 of 9 parent sites and at 6 of 9 mutant sites. Because the mutant and the parent both formed pustules, we repeated the experiment on a second group of subjects. In the second iteration, 2 volunteers were inoculated with 101 CFUs of 35000HP on one arm and with 93, 186, and 372 CFUs of 35000HP.303 on the other arm. Pustules formed at 6 of 6 parent sites and at 3 of 6 mutant sites (table 2) .
Overall (table 3) ; the yields were not statistically different. Histological examination was done on all biopsy specimens as described elsewhere [19, 20] . All biopsy specimens contained micropustules composed of neutrophils within the epidermis and a dermal infiltrat of CD4 + perivascular mononuclear cells. No major differences between mutant and parent pustules were observed (data not shown).
For the parent and mutant broth cultures used to prepare the inocula, all 71 parent colonies and all 72 mutant colonies tested had the expected antibiotic susceptibility (parent, chloramphenicol sensitive; mutant, chloramphenicol resistant). All colonies obtained from surface cultures and biopsy specimens from parent sites ( and , respectively) and mun p 387 n p 156 tant sites ( and , respectively), had the expected n p 319 n p 114 antibiotic susceptibility.
DISCUSSION
Production of AI-2 by luxS has been established for many bacterial species [30] . Although the involvement of the luxS/ AI-2 system in quorum sensing remains to be proven for many of them, inactivation of luxS results in altered virulence phenotypes in some pathogens [5] [6] [7] . In the present study, we have shown (1) that H. ducreyi contains a luxS homologue, (2) that this bacterium is capable of producing an AI-2-like molecule, and (3) that the inactivation of luxS results in modestly reduced infectivity in the human challenge model.
When tested in the V. harveyi-based bioluminescence assay, cell-free culture supernatants from H. ducreyi 35000HP induced luminescence whereas 35000HP.303 had considerably less AI-2 activity, indicating that H. ducreyi produces an AI-2-like molecule that is dependent on the presence of LuxS. Other Pasteurellaceae family members have a functional LuxS/AI-2 regulatory system [8] [9] [10] 38] . When luxS is inactivated in these bacteria, the virulence of the organisms is altered. An Haemophilus influenza luxS mutant has increased virulence in a chinchilla model of middle ear infection [38] , whereas A. pleuropneumoniae and M. haemolytica A1 mutants have reduced virulence in mouse [8] and calf [9] infection models, respectively. In the present study, we showed that inactivation of the luxS gene resulted in a reduced pustule-formation rate compared with that of the parental strain, indicating that this mutant has a partially attenuated phenotype. This is the fourth report of a partially attenuated mutant in 35000HP.
The human model closely simulates the firs 2 weeks of natural chancroid. Lesions are not allowed to progress beyond the pustular stage to ulcers, which are associated with lymphadenitis. In pustules, H. ducreyi forms aggregates; colocalizes with collagen, fibrin neutrophils, and macrophages; and is extracellular [13, 39] . It is possible that H. ducreyi uses the production of AI-2 to alter its gene-regulation profil and to aid in the initiation of infection. Because H. ducreyi maintains similar relationships with host cells in experimental infection and naturally acquired chancroidal ulcers [40] , the expression of luxS may also contribute to the ulcerative stage of disease.
We inactivated the luxS gene by insertion of a cat cartridge. Complementation of the luxS mutant in trans partially restored AI-2 activity. The lower AI-2 activity obtained with the complemented luxS mutant (figu e 2) may be the result of the reduced extent of growth caused by the presence of kanamycin in the growth medium. We are precluded by biosafety considerations from testing complemented mutants in human volunteers. According to the human challenge protocols, we are required to show, by Southern blot and PCR analyses, only that the expected allelic exchange had occurred in the mutant. Subsequent to performing the human challenge trials, we used PCR to amplify the mutated luxS gene and some fl nking DNA from the chromosome of the luxS mutant. Nucleotide sequence analysis showed 2 changes in the flankin ORFs, resulting in 1 amino acid substitution (S762N) in the HD0369 protein and 1 amino acid substitution (I28T) in the HD0371 protein.
We examined the role played by LuxS in the virulence of 35000HP, a class I strain. There are 2 classes of H. ducreyi strains, each of which expresses different variants of several outer membrane proteins and oligosaccharide components of lipooligosaccharide [41] . Whether LuxS plays a role in the virulence of class II strains is unknown.
To our knowledge, this is the firs report of a genital-ulcerdisease pathogen producing an AI-2-like molecule that likely plays a role in virulence. Further studies to determine (1) whether this autoinducer molecule is involved in gene regulation in H. ducreyi, (2) the mechanism by which the luxS/AI-2 system contributes to the virulence of H. ducreyi 35000HP, and (3) whether the luxS gene product plays a role in the virulence of class II H. ducreyi strains [41] are in progress.
